US 11,718,601 B2
Pyridinyl substituted oxoisoindoline compounds
Yan Chen, Yardley, PA (US); Godwin Kwame Kumi, Morrisville, PA (US); Audris Huang, New Hope, PA (US); Satheesh Kesavan Nair, Bangalore (IN); Bharat Dinkar Shimpukade, Bangalore (IN); Suresh Babu Vishwa Krishna Penmetsa, Bangalore (IN); and James Aaron Balog, Lambertville, NJ (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Apr. 5, 2022, as Appl. No. 17/713,598.
Claims priority of application No. 202111016193 (IN), filed on Apr. 6, 2021; and application No. 202111022098 (IN), filed on May 17, 2021.
Prior Publication US 2022/0324840 A1, Oct. 13, 2022
Int. Cl. C07D 401/14 (2006.01); A61P 35/00 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/00 (2018.01)] 39 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
R1 is —NH2;
each R2 is independently F, Cl, —CN, C1-4 alkyl, —CH2F, —CHF2, —CF3, —OCH3, or cyclopropyl;
each R4 is independently F, Cl, —CH3, —CH2F, —CHF2, —CF3, or —OCH3;
R6 is C1-2 alkyl or C1-2 fluoroalkyl;
m is zero, 1, 2, or 3; and
n is zero, 1, 2, or 3.